Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib

Table 2

Change in HAQ-DI score at month 3 (from baseline).

Study	Total (𝑁)	Tofacitinib 5 mg bd	Tofacitinib 10 mg bd	Placebo	Adalimumab 40 mg every 2 weeks
Burmester et al. [15]	399	−0.43§	−0.46§	−0.18	—
Fleischmann et al. [16]	611	−0.50**	−0.57**	−0.19	—
Kremer et al. [17]	792	−0.46§	−0.56§	−0.21	—
van der Heijde et al. [18]	797	−0.40^#	−0.54§	−0.15	—
van Vollenhoven et al. [19]	717	−0.55**	−0.61**	−0.24	−0.49**
Fleischmann et al. [20]	384	−0.51*	−0.66§	−0.25	—
Kremer et al. [21]	507	−0.49**	−0.39*	−0.16	—
Tanaka et al. [22]	140	−0.49**	−0.57**	−0.05	—

∗Significant 𝑃<0.05; **significant 𝑃<0.001; §significant 𝑃<0.0001; ^#significance not declared.